Scott C. Sutton

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 186 citations

Life Sciences, Cancer Biology, Oncology +14

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

Alexei Brooun, K.S. Gajiwala, Ya‐Li Deng et al. · Nature Communications · 2016 · 160 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)

Pei‐Pei Kung, Patrick Bingham, Alexei Brooun et al. · Journal of Medicinal Chemistry · 2017 · 128 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna et al. · Journal of Medicinal Chemistry · 2021 · 117 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Practical Singly and Doubly Electrophilic Aminating Agents: A New, More Sustainable Platform for Carbon–Nitrogen Bond Formation

Padmanabha V. Kattamuri, Jun Yin, Surached Siriwongsup et al. · Journal of the American Chemical Society · 2017 · 87 citations

Natural Sciences, Chemistry, Medicinal Chemistry +12